INTRODUCTION {#S2}
============

Progressive multifocal leukoencephalopathy (PML) is a fatal neurodegenerative disease characterized by lytic JCPyV infection of oligodendrocytes and astrocytes in the CNS ([@R1]; [@R11]). PML occurs in \~3% of patients with HIV, and the mortality rate in AIDS-associated PML cases is approximately 50% ([@R6]; [@R8]; [@R12]; [@R17]). Individuals undergoing immunomodulatory therapy for diseases such as multiple sclerosis (MS) or Crohn's disease are also at risk of developing PML for which there is no treatment ([@R5]; [@R11]; [@R13]; [@R24]). The only option is to restore immune surveillance in these patients.

JCPyV attachment to host cells is mediated by recognition of the receptor motif α2,6-linked glycan lactoseries tetrasaccharide c (LSTc) ([@R24]). JCPyV also requires 5-HT~2~ receptors(5-HT~2A~R, 5-HT~2B~R, and 5-HT~2C~R) to infect cells ([@R2]; [@R7]; [@R16]). The 5-HT~2~Rs are Gα~q/11~-coupled receptors and are composed of seven transmembrane domains, a glycosylated extracellular N-terminal domain, three extracellular loops (ECL1--3), three intracellular loops (ICL1--3), and one intracellular C-terminal tail. The second intracellular loop of all three receptors contains an important structural domain characterized by a DRY motif and by the presence of a proline 6 amino acids downstream of the DRY motif (proline 6). It was previously reported that proline 6 in 5-HT~2C~R is involved in β-arrestin binding ([@R19]). β-arrestin binding to the 5-HT~2~Rs is crucial to initiate internalization because it acts as a scaffold for AP2 and clathrin ([@R3]; [@R32]). Transfection of HEK293A cells, a poorly permissive cell line, with human 5-HT~2~Rs confers susceptibility to infection by facilitating viral entry into host cells, and a function-blocking antibody directed against 5-HT~2A~R inhibits JCPyV infection of glial cells ([@R2]; [@R7]). Drugs targeting one isoform or multiple isoforms of the 5-HT~2~Rs showed different degrees of inhibition to JCPyV infection, suggesting that these receptors may have a cooperative role in JCPyV entry ([@R7] ; [@R26]). JCPyV does not seem to interact with 5-HT~2~Rs at the plasma membrane because JCPyV binding to cells overexpressing the 5-HT~2~Rs is not enhanced ([@R2]). JCPyV enters host cells via clathrin-mediated endocytosis, and the 5-HT~2~Rs are also internalized by the same mechanism ([@R20]; [@R27]; [@R28]). It is not yet known whether there is an interaction between JCPyV and the 5-HT~2~Rs during entry, and studies to clarify whether there is a redundant role for each individual isoform in the context of JCPyV infection of glial cells have not been performed. Additionally, it is not known what structural domains of the 5-HT~2~Rs are crucial for JCPyV infection, although recently a motif in the C terminus of the 5HT~2A~ receptor was shown to be important for virus internalization and infection ([@R20]). In this study, mutagenesis of an ASK (Ala-Ser-Lys) motif in the C-terminal tail of 5HT~2A~R and small interfering RNA(siRNA) knockdown of beta-arrestin reduced JCPyV infection ([@R20]).

In the present work, we exploit the ability of the guide RNA/ caspase 9 (gRNA/Cas9) complex to cause double-strand breaks (DSBs) that are randomly repaired through the non-homologous end joining (NHEJ) pathway ([@R29]). Using CRISPR/Cas9, we generated genetically modified human glial cell lines to investigate the exact role of the three 5-HT~2~R isoforms in JCPyV infection. We isolated single cells and performed clonal expansion and deep sequencing of each clone to ascertain the nature of the gene modifications. This approach allowed us to isolate different mutants for analyses and to compare their susceptibilities to infection by JCPyV. By analyzing a panel of CRISPR mutants, we were able to identify critical motifs in the second intracellular loop of each receptor that were responsible for conferring susceptibility of the cells to infection by JCPyV.

RESULTS {#S3}
=======

JCPyV Transiently Interacts with 5-HT~2A~R, 5-HT~2B~R, and 5-HT~2C~R {#S4}
--------------------------------------------------------------------

SVG-A cells were exposed to JCPyV, and a proximity ligation assay (PLA) was used to test for an interaction between the 5-HT~2~Rs and JCPyV VP1 at 0, 5, and 15 min post-infection ([Figures 1A](#F1){ref-type="fig"}--[1C](#F1){ref-type="fig"}). A significant increase in signal was detected at 5 min post-entry when compared to uninfected cells. There was not an observable increase in signal at 0 min when the virus initially binds to the plasma membrane, supporting our previous observation that JCPyV does not interact with the 5-HT~2~Rs at the cell surface ([@R2]). The interaction between JCPyV and the 5-HT~2~Rs is transient because, at 15 min post-entry, the PLA signal returned to baseline levels. To test JCPyV specificity, the experiment was repeated at 5 min post-infection, targeting JCPyV VP1 and the transferrin receptor (TFR) ([Figure 1D](#F1){ref-type="fig"}). No increase in the PLA signal was detected.

Deletion of the Second Intracellular Loop of the 5-HT~2C~ Receptor Correlates with Reduced Susceptibility to Infection {#S5}
----------------------------------------------------------------------------------------------------------------------

CRISPR-Cas9 was used to directly modify the coding sequence of 5-HT~2A~R, 5-HT~2B~R, and 5-HT~2C~R in SVG-A cells. Briefly, we selected the gRNA sequences from the GeCKOv2 library published by [@R30] and used a single vector lentiviral system to deliver them into SVG-A cells. After lentiviral infection and drug selection, single cells were isolated on rafts and expanded to generate clonal populations. The edited genomes were characterized using next-generation sequencing. Clones displaying nonsynonymous mutations leading to a premature stop codon were selected for further analysis. The gRNA directed against the human 5-HT~2A~R targeted the second intracellular loop coding sequence. One CRISPR-modified clonally expanded cell line was selected (5-HT~2A~R∆1-SVG-A cells). Two sequences carrying different nonsynonymous mutations were identified ([Figures 2A](#F2){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). The DRY motif is disrupted in the first sequence, and it is preserved in the second. After the nonsynonymous mutations, there are 16 amino acids that differ from the wild-type(WT) sequence and they precede a premature stop codon. JCPyV infection of 5-HT~2A~R∆1-SVG-A cells was not inhibited when compared to WT-SVG-A cells ([Figure 2B](#F2){ref-type="fig"}). The gRNA directed against the human 5-HT2BR targeted the third intracellular loop. One CRISPR-modified clonally expanded cell line was selected (5-HT~2~BR∆1-SVG-A cells), and it is characterized by four sequences carrying different 5-HT2BR nonsynonymous mutations ([Figures 2A](#F2){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). JCPyV infection of 5-HT~2~BR∆1-SVG-A cells was not inhibited when compared to WT-SVG-A cells ([Figure 2B](#F2){ref-type="fig"}). The gRNA directed against the human5-HT~2C~R targeted the coding sequence of the second intracellular loop, and the CRISPR-modified sequence obtained from one clone (5-HT~2C~R∆1-SVG-A cells) is shown in [Figures 2A](#F2){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}. Interestingly, the core sequence of the second intracellular loop starting with the DRY motif was completely disrupted, and JCPyV infection of the 5-HT~2C~R∆1-SVG-A cells was significantly inhibited when compared to WT SVG-A cells([Figure 2](#F2){ref-type="fig"}).

Double and Triple Mutants that Include the 5-HT~2C~R Modification Show Reduced Susceptibility to Infection {#S6}
----------------------------------------------------------------------------------------------------------

5-HT~2B~R∆1-SVG-A cells were infected with lentiviral particles encoding for a gRNA targeting 5-HT~2C~R to generate a double mutant 5-HT~2B/2C~R∆1 -SVG-A cell line. The gRNA was the same used to generate 5-HT~2C~R∆1-SVG-A cells. The edited genome of a selected clonal population was characterized by next generation sequencing, and the nonsynonymous mutation was identical to the one described in [Figures 2A](#F2){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}.JCPyV infection of 5-HT~2B/2C~R∆1-SVG-A cells was reduced by \~60% when compared to WT-SVG-A cells, similar to 5-HT~2C~R∆1-SVG-A single mutant([Figure 2B](#F2){ref-type="fig"}). We proceeded to infect 5-HT~2B/2C~R∆1-SVG-A cells with lentiviral particles encoding for a gRNA targeting 5-HT~2A~R to generate a triple 5-HT~2A/2B/2C~R∆1-SVG-A cell line. The gRNA was the same used to generate 5-HT~2A~R∆1-SVG-A cells. The sequencing results are shown in [Figure S1C](#SD1){ref-type="supplementary-material"}. Again, JCPyV infection of 5-HT~2A/2B/2C~R∆1-SVG-A cells was 60% decreased when compared to WT-SVG-A cells similar to 5-HT~2C~R∆-SVG-A cells and 5-HT~2B/2C~R∆1-SVG-A cells ([Figure 2](#F2){ref-type="fig"}). Finally, we generated 5-HT~2A/2B~R∆1-SVG-A cell to WT-SVG-A cells ([Figures 2B](#F2){ref-type="fig"} and[S1B](#SD1){ref-type="supplementary-material"}). Our results indicate that the 5-HT~2C~R receptor was dominant in the presence of truncated 5HT~2A~R and 5HT~2B~R that kept the second intracellular loop intact.

CRISPR-Cas9-Mediated N-Terminal Targeting of5-HT~2A~R and 5-HT~2B~R Significantly Decreases JCPyV Infection {#S7}
-----------------------------------------------------------------------------------------------------------

To confirm that the second intracellular loop of the 5-HT~2~Rs could have a crucial role in facilitating JCPyV entry, gRNA stargeting the N-terminal coding region of 5-HT~2A~R and 5-HT~2B~R were designed. The web-based tool called CRISPR design (<http://zlab.bio/guide-design-resources>) was used, cell lines from single cell clones were generated, and the genome editing was characterized as described previously ([Figure S2A](#SD1){ref-type="supplementary-material"}). JCPyV infection of 5-HT~2A~R∆2-SVG-A cells and 5-HT~2B~R∆2-SVG-A cells was reduced compared to WT and had the same phenotype as the 5-HT~2C~R∆-SVG-A cells ([Figure 3A](#F3){ref-type="fig"}). Transfection of the mutant cell lines with plasmids expressing the WT versions of 5-HT~2A~R, 5-HT~2B~R, and 5-HT~2C~R partially rescued infection, confirming that our gRNAs were specific for the chosen targets ([Figure 3B](#F3){ref-type="fig"}). To determine whether JCPyV infection could be completely abolished by targeting all three receptors at the same time, triple mutant cell lines were generated using the custom design gRNAs to target 5-HT~2A~R and 5-HT~2B~R and the gRNA obtained from the GeCKOv2 library to target 5-HT~2C~R, and sequencing results are shown in [Figure S2B](#SD1){ref-type="supplementary-material"} (5-HT~2A/2B/2C~R∆2-SVG-A cell line). JCPyV infection of the triple mutant was modestly reduced when compared to single mutants. The transfection of plasmids expressing the WT form of either 5-HT~2A~R, 5-HT~2B~R, or 5-HT~2C~R partially rescued JCPyV infection of 5-HT~2A/2B/2C~R∆2-SVG-A cell line ([Figure 3C](#F3){ref-type="fig"}). As a control, we infected 5-HT~2A/2B/2C~R∆2-SVG-A cells with SV40 and saw no difference in susceptibility to infection compared to WT cells ([Figure 3D](#F3){ref-type="fig"}). We then tested JCPyV binding and entry in 5-HT~2A/2B/2C~R∆2-SVG-A cells compared to WT SVG-A. Virus binding was measured by flow cytometry using labeled JCPyV-488. The binding of labeled virus to the triple knockout was not reduced compared to WT ([Figure 3E](#F3){ref-type="fig"}). We then tested for JCPyV entry by JC pseudovirus (JCPsV) transduction. JCPsV has been shown to mirror JCPyV attachment and entry, and it does not have the ability to replicate making it a good tool to test for viral entry defects ([@R9]). We found that JCPsV transduction of 5-HT~2A/2B/2C~R∆2-SVG-A cells was significantly decreased when compared to WT SVG-A cells ([Figure 3F](#F3){ref-type="fig"}).Finally, we treated 5-HT~2A/2B/2C~R∆2-SVG-A cells with ritanserin, a 5-HT~2~R antagonist, at a 25 µM concentration and found that JCPyV infection could be further reduced ([Figure 3G](#F3){ref-type="fig"}).

The Second Intracellular Loop of the 5-HT~2~Rs Is Important for JCPyV Infection {#S8}
-------------------------------------------------------------------------------

We hypothesized that the difference in the infection phenotypes between 5-HT~2C~R∆1-SVG-A cells and in 5-HT~2A~R∆1 and 5-HT~2B~R∆1-SVG-A cells could be due to incomplete disruption of the second intracellular loop (ICL-2). We generated truncation mutants of the three receptors by inserting a stop codon either before the beginning of ICL-2 or at the end of the fourth trans-membrane domain ([Figure 4A](#F4){ref-type="fig"}). We transfected HEK293A cells with WT or the truncation mutants and challenged with JCPyV. Overexpression of WT receptors supported JCPyV infection as previously reported ([@R2]). The receptors truncated at the end of the fourth transmembrane domain showed a significant increase in JCPyV infection when compared to cells transfected with the empty vector. In contrast, receptors that were truncated before the beginning of ICL-2 did not support JCPyV infection. WT and truncation mutant receptors were equally expressed at the cell surface ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). The second intracellular loop of all three WT receptors contains an important structural domain characterized by a DRY motif and by the presence of a proline, 6 amino acids downstream of the DRY motif (proline 6; [Figure 4B](#F4){ref-type="fig"}). It was previously reported that proline 6 in 5-HT~2C~R is involved in barrestin binding, which initiates internalization and could trigger specific signaling cascades ([@R19]). We mutated proline 6 to an alanine in 5-HT~2A~R-YFP, 5-HT~2B~R-YFP, and 5HT~2C~R-YFP fusion constructs and transfected HEK293A cells with either the WT or the mutated version of the receptors ([Figure 4c](#F4){ref-type="fig"}). Overexpression of the proline to alanine mutant receptors impaired JCPyV infection. The proline-to-alanine mutant receptors were equally expressed at the cell surface when compared to WT receptors ([Figures S3C](#SD1){ref-type="supplementary-material"} and [S3D](#SD1){ref-type="supplementary-material"}). To determine whether there is a link between β-arrestin and 5-HT~2~R-mediated JCPyV infection, we treated WT and 5-HT~2A/2B/2C~R∆2-SVG-A cells with siRNA targeting β-arrestin (β-arrestin KD) or a non-targeting oligonucleotide (neg). Efficient knockdown was tested by western blot. Knockdown of β-arrestin in WT SVG-A cells causes a significant reduction in JCPyV infection, although it does not reduce infection further in 5-HT~2A/2B/2C~R∆2-SVG-A cells. Strikingly, the infection in 5-HT~2A/2B/2C~R∆2-SVG-A cells is similar to WT SVG-A cells treated with β-arrestinsiRNA ([Figure 4D](#F4){ref-type="fig"}).

DISCUSSION {#S9}
==========

JCPyV requires the 5-HT~2~Rs to facilitate entry into host cells, and here, we demonstrated that the virus transiently interacts with each of the 5HT~2~Rs during entry. Our approach using CRISPRCas9 allowed us to uncover an important role for the second intracellular loop of the 5-HT~2~Rs specifically of a proline located 6 amino acids downstream of the DRY motif. The first set of gRNAs used in this study generated premature stop codons at the end of the second intracellular loop of 5-HT~2A~R, in the middle of the third intracellular loop of 5-HT~2B~R, and at the beginning of the second intracellular loop of 5-HT~2C~R. JCPyV infection was significantly decreased in 5-HT~2C~R∆1-SVG-A cells but was not in 5-HT~2A~R∆1 and 5-HT~2B~R∆1-SVG-A cells. The generation of a triple mutant cell line containing these modifications did not further decrease JCPyV infection when compared to 5-HT~2C~R∆1-SVG-A cells, indicating that the missense mutations in 5-HT~2A~R and 5-HT~2B~R were not affecting JCPyV infection ([Figure 2](#F2){ref-type="fig"}). However, when clonal cell lines were generated using gRNAs targeting the extreme N terminus of 5-HT~2A~R and 5-HT~2B~R, JCPyV infection was significantly decreased to levels equal to those observed in 5-HT~2C~R∆1-SVG-A cells ([Figure 3](#F3){ref-type="fig"}). These data suggested that the second intracellular loop of the 5-HT~2~Rs plays a critical role in facilitating virus infection. The second intracellular loop of the 5HT~2~Rs contains a contiguous stretch of 10 amino acids beginning with the DRY motif and followed by a proline 6 amino acids downstream. This residue has been shown to be important for β-arrestin binding in the 5-HT~2C~R ([@R19]). When we mutated the proline to an alanine in all three constructs encoding the 5-HT~2~Rs, JCPyV infection was significantly decreased, but not eliminated ([Figure 4B](#F4){ref-type="fig"}). β-arrestin has also been shown to bind to the third intracellular loop and to the C-terminal tail of the 5-HT~2~Rs ([@R10]; [@R19]; [@R21]). Hence, this would explain the residual infection of HEK293A cells transfected with proline to alanine mutant receptors. This may also explain why the infection in cells transfected with the receptors truncated after the DRY motif was not as efficient as infection of WT cells ([Figure 4A](#F4){ref-type="fig"}). We next confirmed a role for β-arrestin in JC virus infection by knocking it down with siRNA, and our results were consistent with that reported by [@R20]. siRNA treatment of WT cells decreased infection to the same extent as what we observed in the of 5-HT~2A/2B/2C~R∆2-SVG-A triple mutant cells. The fact that siRNA knockdown of β-arrestin did not reduce infection further in the triple mutant cells suggests that β-arrestin is exerting its main effect on infection by interacting with the 5HT~2~Rs. The residual infectivity in these experiments could be due to the presence of minor splice variants of the 5-HT~2A~R and 5-HT~2B~R not targeted by the custom designed gRNAs or by different and unknown entry receptors that do not rely on β-arrestin. The ritanserin experiment suggests that unknown minor splice variants could be the culprit; however, we used a non-toxic but relatively high concentration of the drug (25 µM) and it has been reported that, at such concentrations, ritanserin could also inhibit histamine-H1, dopamine-D2, adrenergic α1, and α2 receptors ([@R14]).

The most prominent effect on JCPyV infection was obtained by individual receptor mutations, suggesting that the 5-HT~2~Rs do not have a redundant role ([Figure 3A](#F3){ref-type="fig"}). It has been reported that 5-HT~2~Rs form homodimers and heterodimers in vitro and in vivo ([@R22]). Based on our findings, we hypothesize that JCPyV may favor 5-HT~2~ receptor heterodimers over homodimers to initiate infection. Nonetheless, when we overexpressed one 5-HT~2~ receptor isoform at a time in the triple mutant cell line, we were able to partially rescue the JCPyV infection phenotype ([Figure 3C](#F3){ref-type="fig"}). This suggests either that JCPyV uses homodimers of 5-HT~2~ receptors as well or that there are unknown entry receptors that function in synergy with the 5-HT~2~ receptors. Further experiments are needed to investigate these hypotheses.

STAR★METHODS {#S10}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S12}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Walter J. Atwood (<walter_atwood@brown.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Cell lines {#S14}

SVG-A cells, HEK293A (CRL-1573), HEK293T (ATCC CRL-11268), Lenti-X HEK293T cells (takara, cat\# 632180) and African green monkey (CV-1) (ATCC, CCL-70) cells were used. SVG-A cells are a third-generation sub clone of the original SVG cell line ([@R18]) and express the astrocyte marker GFAP. SVG-A cells and CV-1 were cultured in MEM supplemented with 10% fetal bovine serum and 1% of Amphotericin B, Penicillin, Streptomycin solution. HEK293A and HEK293T were cultured in DMEM supplemented with 10% fetal bovine serum and 1% of Amphotericin B, Penicillin, Streptomycin solution. All cells were grown in an incubator at 37°c with 5% CO~2~. SVG-A cells and HEK293A cells were authenticated using the ATCC cell line authentication service (STR profile). They have a 55% match with SVG p.12 (human fetal glial cells, CRL-8621) from ATCC and they are of male origin. HEK293A cells have an 81% match with the parental line and are of female origin. We are in the process of authenticating the other cell lines used in the study.

### Virus and pseudovirus {#S15}

For JCPyV infection we used a lab adapted strain referred to as Mad-1/SVED described previously ([@R33]). JCPyV was grown in SVG-A cells using 1700 cm^2^ roller bottles at 5% CO~2~ and at 37°c. Cells were cultured for 14 days, with the cell culture media replaced at 7 days. Viral lysates were harvested by scraping cells in the presence of cell culture media. This lysate was frozen at 80C and thawed in a 37°c water bath 3 times. Deoxycholate was added to obtain a final concentration of 0.25%. Samples were spun at 17000 x g for 30 mins and supernatant was used for infections. Simian virus 40 (SV40) strain 776 was propagated in the African green monkey kidney cell line CV-1 as previously described following the same protocol described for JCPyV ([@R25]). JCPyV lysates, when needed, were purified as previously described ([@R15]; [@R23]). Briefly, lysates were sonicated three times on ice (50% amplitude 50% duty cycle, power 4, 1 min) and treated with Neuraminidase type II (Sigma, Cat\# N6514) at 37°c for 1 hr to release virus from membranes. Samples were subjected to two rounds of Vertrel XF (Fisher scientific NC9715008) to extract lipids. The viral supernatant was pelleted through a 20% sucrose cushion in a Beckman SW40ti rotor at 150,000 x g at 4°c for 3 h. The viral pellet was resuspended into buffer A (10mM Tris-HCl, 50 mMNaCl, 0.1 mM CaCl2) and sonicated 3 times (30% amplitude 50% duty cycle, power 3, 1 min). The resuspended pellet was loaded onto a CsCl step gradient (1.29--1.35 g/ml) and spun at 115,000 x g at 4°C for 18 h in a Beckman SW55ti rotor. The band corresponding to DNA-containing virions was isolated and dialyzed extensively against buffer A. If needed JCPyV was directly labeled with Alexa Fluor 488 following to the manufacturer protocol (ThermoFisher Scientific, cat\# A20000). JC pseudovirus (JCPsV) was generated as described previously ([@R9]). Briefly, pseudoviruses were produced by transfection of the VP1, VP2, VP3 and pSV40-Cluc plasmids into HEK293FT cells using the FuGENE® 6 Transfection Reagent (PromegaMadison, WI USA cat \# E2692) in a 3:1:1:2 ratio. Mock pseudovirus controls were generated by transfecting 293FT cells with non-specific DNA (ns-DNA) and the pSV40-Cluc (NEB \# N0318) reporter plasmid in a 5:1 ratio and following the same production/purification protocol as pseudovirus. As the viral structural proteins are expressed, they assemble into pseudovirus particles and package available plasmid DNA. The media is changed on the day following transfection to remove any extracellular transfection reagent. Cells were harvested 6 days post transfection and pseudovirus was purified as described above. Secreted luciferase was measured with the BioLuxCypridina Luciferase Assay kit (NEB E3309L).

METHOD DETAILS {#S16}
--------------

### Antibodies {#S17}

A mouse monoclonal antibody obtained from the supernatant of a hybridoma was used to detect JCPyV VP1 (PAB597). Rabbit polyclonal primary antibodies were used to recognize the 5-HT~2~Rs and TFR in the proximity ligation assay. Anti-5-HT~2A~R and anti 5HT~2C~R were obtained from LS Biosciences, Inc cat\# LS-A1106 and LS-A1119 respectively. Anti-5-HT~2A~R recognizes the N terminus while anti-5-HT~2C~R the C terminus. Anti-5-HT~2B~R was obtained from Novus Biologicals cat\# NLS1111 and recognizes the second extracellular loop. Anti-TFR was purchased from Novus Biologicals cat\# NB100--92243. For Western Blot analysis a rabbit monoclonal anti-β-arrestin½ was purchased from Cell Signaling Technologies (\#4674) and a mouse monoclonal anti-GAPDH was purchased from Sigma-Aldrich (G8795). A Mouse monoclonal anti-pan Cadherin antibody was used as cell surface marker (abcam, ab6528) and Rabbit polyclonal anti-6X His tag was used to stain for truncated receptors (abcam, ab9108).

### Indirect immunofluorescence assay {#S18}

Three days (for SVG-A cells) or five days (for HEK293A cells) following viral challenge, cells were stained and counted by eye using epifluorescence microscopy (Nikon E800) as previously described ([@R2]). Briefly, plates were fixed using ice-cold 100% methanol at 20C for at least 20 mins. They were treated with PBS containing 1% Triton X-100 for 5 mins and blocked with 10% goat serum for 30 mins at Room Temperature (RT). Samples were incubated for 1 hr at 37°C with PAB 597 (1:50) followed by staining with secondary antibody conjugated to Alexa Fluor 488 (Thermo Fisher Scientific) (1:500) and DAPI (Thermo Fisher Scientific). The amount of DAPI and VP1 stained nuclei per visual field was counted using Cell Profiler ([@R4]) and data are expressed as percentage of infected cells/visual field. Cells plated on coverslips and transfected with all mutant receptors were fixed with freshly made 4% PFA for 20 mins, permeabilized with Triton-X 1% for 15 mins, blocked with 10% goat serum for 30 mins. Cells transfected with truncated mutant receptors were incubated O/N with anti-6X His tag at 1/100 dilution in 2% goat serum. The next day cells were washed with PBS 1X and incubated with anti-pan Cadherin for 2 hr at 37°C in 2% goat serum. Cells were washed and incubated with anti-rabbit 488 and anti-mouse 594 at 1/500 dilution in PBS 1X at 37°C for 1 hr. Cells were washed with PBS 1 X and stained with 1/1000 DAPI solution (ThermoFisher Scientific, Cat\# 62248) for 10 mins then mounted on slides.

### Proximity ligation assays {#S19}

To visualize close proximity between JCPyV VP1 and the 5-HT~2~Rs, WT-SVG-A cells were pre-chilled at 4°C for 20 mins and infected with purified JCPyV on ice for 1 hr. Three time points were analyzed, 0, 5, and 15 mins post infection. For the 0 mins time point cells were washed and fixed with 4% PFA immediately after infection. For the 5 and 15 mins time points, the virus was aspirated off, warm complete media was added, and the cells were shifted at 37°C for the respective time before fixation. Cells were permeabilized with PBS containing 0.5% Triton X-100 and were then blocked in 5% Donkey Serum. Cells were then stained for VP1 (1:2000 dilution) and 5-HT~2~Rs (1:25 dilution) or TFR (1:50 dilution) by overnight incubation at 4°C. These cells were then immunostained using the proximity ligation assay, following manufacturer's instructions (Bethyl Labs). Cells were washed, and the cell nuclei were counterstained using DAPI. Fluorescence micrographs were collected by confocal microscopy. Fluorescent foci were quantified using the Blobfinder program (<http://www.cb.uu.se/amin/BlobFinder/>). As negative control uninfected samples were stained and processed at the same time. Blobfinder analysis was performed using a 7 by 7 blob size and at least 50 cells per sample were analyzed. The average number of blobs counted in the uninfected cells was subtracted from the infected samples. Experiments were performed in triplicate and error bars denote standard error.

### Generation of CRISPR modified SVG-A clonal cell lines {#S20}

The lentiCRISPRv2 plasmid with a puromycin resistance was obtained from Addgene (\#52961). Two additional lentiCRISPRv2 plasmids were generated by replacing the puromycin resistance with neomycin or hygromycin resistance to generate double or triple mutants. The lentiCRISPRv2 plasmid was mutated to insert aHpaI site after the puromycin resistance gene using Agilent QuikChange II XL Site Directed Mutagenesis Kit (\#200521). Primers were ordered from Integrated DNA Technologies (IDT): lentiCRISPRv2\_ g9959c_F GTTGATTGTCGAGTTAACGCGTTCAGGCACCG and lentiCRISPRv2\_ g9959c_R CGGTGCCTGAACG CGTTAACTCGACAATCAAC. The puromycin resistance gene was removed from lentiCRISPRv2 by digesting with BamHI and HpaI and sequences encoding neomycin or hygromycin resistance were cloned into the lentiCRISPRv2 vector. The DNA encoding for the neomycin and hygromycin resistance were ordered from Blue Heron Biotech, LLC. The gRNAsequences targeting IL2 or IL3 of the 5-HT~2~Rs were obtained from the GeCKOv2 human library published by [@R30]. 5-HT~2A~R: GATTCTGGATGGC GACGTAG 5-HT~2B~R: AGCCACCTCAACGCCTAACA 5-HT~2C~R: GCACCTCTGCGCTATATCGC. The gRNAs targeting the N terminus of 5-HT~2A~R and 5-HT~2B~R were designed using a web-based tool called CRISPR design (<http://zlab.bio/guide-design-resources>). 5-HT~2A~R: AAAGTCATTACTGTAGAGCC 5-HT~2B~R: GTTATCTCTTCTAACTGGTC. The protocol provided by the Zhang lab was used to clone specific gRNAs in the lentiCRISPRv2 plasmids with minor changes (<https://media.addgene.org/data/plasmids/52/52961/52961-attachment_B3xTwla0bkYD.pdf>). Lentiviral particles were packaged in Lenti-X HEK293T cells plated in T75 cm^2^ flasks using the pCMV-dR8.2 packaging plasmid (<https://www.addgene.org/8455/>) and the VSV-G envelope encoding plasmid ([www.addgene.org/8454/](http://www.addgene.org/8454/)) at a ratio of 3 (pCMV-dR8.91), 0.3 (VSV-G) and 3 (lentiCRISPRv2). Fugene HD (Promega) was used at a 3:1 DNA:Fugene ratio for transfection following manufacturer instructions. Cells were incubated for 18 hr then media was replaced with 10 mls of DMEM with 30% FBS and cells were incubated at 37°C for 24hrs. Lentivirus was harvested every 12 hr, for a total of three harvests. Supernatants were combined filtered using a 0.45 µm filter and either used to infect SVG-A cells immediately or frozen at 80°C. SVG-A cells 60% confluent in a T75 cm^2^ flask were infected three times every 24 hr with 10 mls of the filtered lentivirussupplemented with Polybrene (Santa Cruz Biotechnology) at a concentration of 8 μg/ml. Cells were then drug selected with the suitable antibiotic: puromycin was used at 5 μg/ml for 3 days, geneticin (G418) at 600 μg/ml for 1 week and Hygromycin was used at 250 μg/ml for 4 days. Single cell isolation and expansion was performed to obtain a clonal population using Cellraft System (Cell Microsystem). The genome editing was confirmed using the CRISPR deep sequencing service performed at the Center for Computational and Integrative Biology (CCIB) DNA core at the Massachusetts General Hospital (MGH).

### Flow cytometry {#S21}

Cells were washed with 1X PBS and removed from plates using a cell stripper (Cellgro). The cells were pelleted, washed, and incubated in 100 µl of 1X PBS with JCPyV labeled with Alexa Fluor 488 (JCPyV-488) for 1 h on ice with occasional agitation. The cells were pelleted and washed with 1X PBS twice, then fixed in 1% paraformaldehyde (PFA), and analyzed for virus binding using a BD FACSCalibur (BD Bioscience).

### Treatment of cells with ritanserin {#S22}

Treatment with ritanserin was performed as described previously ([@R26]). Briefly, cells at 60% confluence were pretreated with ritanserin (Tocris Bioscience) at 25 µM concentration O/N in complete medium at 37°c. The cells were then prechilled for 30 mins and infected on ice with JCPyV for 1 h in plain MEM 1X. The cells were washed with 1X PBS and warmed MEM with 10% FBS, antibiotics and ritanserin at 25 µM was added. The cells were stained for VP1 after 72 hr as described above.

### Transient transfection {#S23}

CRISPR-modified SVG-A clonal cell lines were plated in 24-well plates in MEM with 10% FBS overnight without antibiotics. Cells at 80% confluence were transfected using Lipofectamine 3000 (Invitrogen) following the manufacturer instructions with 1--2 μg of DNA per well of human 5-HT~2A~R, 5-HT~2B~R or 5-HT~2C~R in pcDNA3.1 or pcDNA3.1 control vector. The cells were incubated at 37°C for 4 h, the medium was replaced with MEM containing 10% FBS and antibiotics and incubated at 37°C for 24--48 hr. Cells were then infected with JCPyV for 1 hr at 37°C and stained for VP1 72 hr later. HEK293A cells were plated on glass coverslips in 24 well plate in DMEM with 10% FBS overnight without antibiotics. Cells at 80% confluence were transfected using Lipofectamine 3000 (Invitrogen) following the manufacturer instructions with 1--2 μg of DNA per well of each mutant receptor construct (either with point mutation or truncated) as well as the appropriate WT control. The cells were incubated at 37°C for 4 h, the medium was replaced with DMEM containing 10% FBS and antibiotics and incubated at 37°C for 48 hr. Cells were fixed and stained as described in the ''immunofluorescence assay'' section.

### Site directed mutagenesis of 5-HT2Rs constructs {#S24}

5-HT~2~Rs-YFP fusion constructs were generated as described previously ([@R2]; [@R16]). Proline180, proline 160 and proline 159 of 5-HT~2A~R, 5-HT~2B~R or 5-HT~2C~R respectively were mutated to an alanine using the QuikChange II Site directed mutagenesis kit by Agilent following manufacturer instructions. XL-1 Blue super competent bacterial cells were used. Mutagenesis primers were designed using the QuikChange primer design tool (<https://www.chem.agilent.com/store/primerDesignProgram.jsp>):

  ------------------- -------------------------------------------
  5-HT~2A~R P180A_F   TGGTGGATGGCATTCTGGATGGCGACGTAG
  5-HT~2A~R P180A_R   CTACGTCGCCATCCAGAATGCCATCCACCA
  5-HT~2B~R P160A_F   GATTGGCCTGGATTGCCTTTTTGATGGCTATGTAACG
  5-HT~2B~R P160A_R   CGTTACATAGCCATCAAAAAGGCAATCCAGGCCAATC
  5-HT~2C~R P159A_F   GAAACGGCTATGCTCAATAGCATTACGTATTGCTACATACC
  5-HT~2C~R P159A_R   GGTATGTAGCAATACGTAATGCTATTGAGCATAGCCGTTTC
  ------------------- -------------------------------------------

Human 5-HT~2A~R, 5-HT~2B~R or 5-HT~2C~R in pcDNA3.1 expression vectors were used to generate truncation mutant receptors. A His tag was added before the stop codon in every mutant, as well as a XhoI cut site and an extra T (CATCATCATCACCACCAC TAA CTCGAG T). Primers were designed using the NEBaseChanger tool (<http://nebasechanger.neb.com/>) and the Q5 Site-Directed Mutagenesis Kit by NEB was used following manufacturer instructions. 5-HT~2A~R was truncated at position 510 (before the DRY motif) and at position 648 (after the DRY motif, at the end of the fourth transmembrane domain). 5-HT~2B~R was truncated at position 450 (before the DRY motif) and at position 579 (after the DRY motif, at the end of the fourth transmembrane domain). 5-HT~2C~R was truncated at position 447 (before the DRY motif) and at position 582 (after the DRY motif, at the end of the fourth transmembrane domain). Human 5-HT~2A~R, 5-HT~2B~R, or 5-HT~2C~R in pcDNA3.1 expression vectors were modified with the addition of a His tag at the C-terminal end of the protein. A BamHI site was added at the very end to help screen colonies (CATCATCATCACCACCAC TAA GGA TCC). Primers were designed using the NEBaseChanger tool (<http://nebasechanger.neb.com/>) and the Q5 Site-Directed Mutagenesis Kit by NEB was used following manufacturer instructions. All Primers were synthesized by Integrated DNA Technologies (IDT).

  -------------------- --------------------------------------------
  2A_trunc_510_His_F   ccactaactcgagtCTGGACCGCTACGTCGCC
  2A_trunc_510_His_R   tggtgatgatgatgCGAGATGGCGCAGAGGTG
  2B_trunc_450_His_F   ccactaactcgagtGTGGATCGTTACATAGCC
  2B_trunc_450_His_R   tggtgatgatgatgTGAAATGGCACAGAGATG
  2C_trunc_447_His_F   ccactaactcgagtCTGGATCGGTATGTAGCAATAC
  2C_trunc_447_His_R   tggtgatgatgatgCGATATAGCGCAGAGGTG
  2A_trunc_648_His_F   ccactaactcgagtGACGATTCGAAGGTCTTTAAG
  2A_trunc_648_His_R   tggtgatgatgatgCTGTAGCCCAAAGACTGG
  2B_trunc_579_His_F   ccactaactcgagtGGGATAGAGACTGATGTG
  2B_trunc_579_His_R   tggtgatgatgatgTTTAATAGGGACTGGAATG
  2C_trunc_582_His_F   ccactaactcgagtAGGGACGAAGAAAAGGTG
  2C_trunc_582_His_R   tggtgatgatgatgCAGTCCAATCACAGGGATAG
  2AWT_His_F           ccactaaggatccCTCGAGTCTAGAGGGCCC
  2AWT_His_R           tggtgatgatgatgCACACAGCTCACCTTTTCATTC
  2BWT_His_F           ccactaaggatccCTCGAGTCTAGAGGGCCC
  2BWT_His_R           tggtgatgatgatgTACATAACTAACTTGCTCTTCAGTTTTG
  2CWT_His_F           ccactaaggatccCTCGAGTCTAGAGGGCCC
  2CWT_His_R           tggtgatgatgatgCACACTGCTAATCCTTTCGC
  -------------------- --------------------------------------------

### siRNA knock-down of β-arrestin {#S25}

β-arrestin specific siRNA and control siRNA were obtained from Cell Signaling Technologies (SignalSilenceβ-arrestin1 siRNA \#6218 and SignalSilence Control siRNA (unconjugated \#6568) and were used at a concentration of 100 nM. Following manufacturer instructions, reverse transfection was performed using 1.5 μl of lipofectamine RNAiMAX and 60,000 cells per well of a 24 well plate or 7.5 μl of lipofectamine RNAiMAX and 300,000 cells per well of a 6 well plate. Cells were incubated for 72hrs then infected with JCPyV (24 well plates) or lysates were harvested for Western Blot (6 well plates).

### Western blot {#S26}

One well of a 6 well plate treated with β-arrestin1 specific siRNA or control siRNA was washed with ice-cold PBS 1X, Cells were incubated for 5 mins on ice in 350 μl of pre-chilled RIPA buffer supplemented with a protease inhibitor cocktail (Complete ULTRA tablets, Mini by Sigma-Aldrich/Roche). Cells were scraped and transferred to a microcentrifuge tube. Cells were rocked at 4°C for 30 mins then centrifuged for 15 mins at 14,000 rpm at 4°C. Supernatants were mixed with sample buffer, boiled for 5 mins at 95°C and resolved by SDS-PAGE (4%--15% Tris-HCl polyacrylamide gel). Proteins were transferred to a nitrocellulose membrane by Semidry transfer, blocked with 1X TBS 1% casein blocker (BioRad \#161--0782) for 1hr at RT then incubated with anti-β-arrestin1/ 2 (1:500) O/N at 4°C. The membrane was washed 4 times with 1X TBS-T then incubated with goat anti-rabbit Alexa 680 (1:5,000) at RT for 1 hr, washed thoroughly with 1X TBS-T and imaged using the ChemiDoc MP Image system (BioRad). The membrane was then probed with anti-GAPDH (1:10,000) O/N at 4°C, washed 4 times with 1X TBS-T then incubated with goat anti-rabbit IRDye CW 800 (1:5,000) for 1 h at RT, washed thoroughly with 1X TBS-T and imaged using the ChemiDoc MP Image system (BioRad).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

Information about the data quantification and statistical analysis is described in the figure legends. A Student's t test was used to calculate the p value of each experiment using Microsoft Excel.

Blobfinder program (<http://www.cb.uu.se/~amin/BlobFinder/>) was used to determine the number of fluorescent foci per cell in the proximity ligation assay quantification shown in [Figure 1](#F1){ref-type="fig"}.

Fiji was used to determine the Mander's coefficient showed in [Figure S3](#SD1){ref-type="supplementary-material"} using the plug in Coloc 2.

Supplementary Material {#SM1}
======================

Work in the Atwood lab was supported by grants from the National Institute of Neurological Disease and Stroke, R01NS043097 and P01NS065719. Work in the Maginnis lab was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the NIH under grant number P20GM103423 (M.S.M.).

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.04.067>.

DECLARATION OF INTERESTS

The authors declare no competing interests.

![JCPyV Transiently Interacts with 5-HT~2A~R, 5-HT~2B~R, and 5-HT~2C~R during Entry\
Close proximity between the major capsid protein VP1 and either 5-HT~2A~R (A), 5-HT~2B~R (B), 5-HT~2C~R (C), or transferrin receptor (TFR) (D) was quantified by PLA assay. The number of green fluorescent foci per cell was quantified using the BlobFinder software. The average number of foci per cell from samples that were not incubated with JCPyV was subtracted from the average number of foci per cell obtained from samples that were incubated with JCPyV. Experiments were performed in triplicate, and at least 50 cells per replicate were analyzed. Error bars represent SD. \*p \< 0.05. Representative images at 5 min post-entry in the presence (~+~JCPyV) or absence of JCPyV (--JCPyV) are included in each panel.](nihms-1529703-f0002){#F1}

![Deletion of the Second Intracellular Loop of the 5-HT~2C~R Correlates with Reduced Susceptibility to Infection\
(A) The protein sequence of the 5-HT~2A~R∆1 (R-2A∆1), 5-HT~2B~R∆1 (R-2B∆1), and 5-HT~2C~R∆1 (R-2C∆1) compared to the WT is shown. Red letters highlight where the frameshift occurred, and the star indicates the stop codon.\
(B) WT and genetically modified SVG-A cell lines were infected with JCPyV for 1 h at 37°c, and cells were stained for VP1. VP1-and DAPI-positive nuclei per visual field were quantified. Percent infection in WT SVG-A cells was set to 100% and the results normalized to this value. The results represent the average of three independent experiments performed in triplicate; at least 15 fields of view were imaged per replicate. Error bars represent SEM. \*p \< 0.05.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1529703-f0003){#F2}

![CRISPR-Cas9-Mediated N-Terminal Targeting of 5-HT~2A~R and 5-HT~2B~R Significantly Decreases JCPyV Infection\
5-HT~2A~R∆2-SVG-A (R-2A∆2), 5-HT~2B~R∆2-SVG-A (R-2B∆2), and 5-HT~2A/2B/2C~R∆2-SVG-A (R-2A/2B/2C∆2) cells were generated.\
(A) Mutant cell lines were challenged with JCPyV and infection scored.\
(B and C) 5-HT~2A~R∆2-SVG-A (R-2AD2), 5-HT~2B~R∆2-SVG-A (R-2B∆2), and 5-HT~2C~R∆1-SVG-A (R-2B∆1) cells (B) and the triple mutant cells (C) were rescued by transfecting the cells with plasmids expressing WT receptors.\
(D) SV40 infection was scored, and it was not reduced in triple mutant SVG-A cells compared to WT.\
(E) JCPyV-488 binding was tested by flow cytometry and was not reduced in triple-mutant SVG-A cells compared to WT.\
(F) WT or triple-mutant cells were transduced with JC pseudoviruses (JCPsV) and luciferase activity measured as relative light units (RLUs) on a log scale. JCPsV entry was significantly reduced in triple-mutant cells.\
(G) The 5HT~2~Rs antagonist ritanserin inhibits JCPyV infection in the triple-mutant SVG-A cells.\
(A, B, C, D, and G) VP1-and DAPI-positive nuclei were quantified, and results are expressed as percent of infected cells. Numbers were normalized to WT SVG-A cellsinfection level (A, D, and G) or to mock transfected cells (B and C), set to either 100% (A, D, and G) or 1% (B and C). All results represent the average of three independent experiments performed in triplicate. At least 15 fields of view were imaged per replicate for the infection experiments. At least 10,000 events wererecorded per replicate in (E). Error bars represent SEM. \*p \< 0.05.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1529703-f0004){#F3}

![The Second Intracellular Loop of the 5-HT~2~Rs Is Important for JCPyV Infection\
(A) HEK293A cells were transfected with WT or truncated constructs, challenged with JCPyV, and stained for TAg.\
(B and C) The proline located 6 amino acids downstream of the DRY motif was mutated to an alanine in three constructs expressing 5-HT~2A~R, 5-HT~2B~R, or 5-HT~2C~R-YFP (B). HEK293A cells were transfected with WT or mutated constructs, challenged with JCPyV, and stained for Tag (C). Results are expressed as Tag-positive cells per visual field.\
(D) WT and 5-HT~2A/2B/2C~R∆2-SVG-A (R-2A/2B/ 2C∆2) were treated with either a non-targeting or β-arrestin1-specific siRNA for 3 days and then challenged with JCPyV. VP1-and DAPI-positive nuclei were quantified, and results are expressed as percent of infected cells.\
Numbers were normalized to WT SVG-A cells infection level, set to 100%. The results represent the average of either three or two independent experiments performed in triplicate, and at least 15 fields of view were counted per replicate. Error bars represent SEM. \*p \< 0.05. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1529703-f0005){#F4}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                              SOURCE                                                   IDENTIFIER
  ------------------------------------------------ -------------------------------------------------------- --------------------------------------------------------------
  Antibodies                                                                                                
                                                                                                            
  Mouse monoclonal anti-SV40 VP1 (PAB597)          lab generated, cross-reacts with JCPyV VP1               N/A
  Rabbit polyclonal anti-5-HT~2A~R                 LS Biosciences                                           cat\#LS-A1106; RRID: AB_10645379
  Rabbit polyclonal anti-5-HT~2B~R                 Novus Biologicals                                        cat\#NLS1111; RRID: RRID:AB_343312
  Rabbit polyclonal anti-5-HT~2C~R                 LS Biosciences                                           cat\#LS-A1119; RRID: AB_592691
  Rabbit polyclonal anti-transferrin receptor      Novus Biologicals                                        cat\#NB100--92243; RRID: AB_1216384
  Rabbit monoclonal anti-β-arrestin1/2             Cell signaling Technologies                              Cat\#4674; RRID: AB_10547883
  mouse monoclonal anti-GAPDH                      Sigma-Aldrich                                            Cat\#G8795 RRID:AB_1078991
  Mouse monoclonal anti-pan Cadherin               Abcam                                                    Cat\#ab6528; RRID:AB_305544
  Rabbit polyclonal anti-6X His tag                Abcam                                                    Cat\#ab9108; RRID:AB_307016
                                                                                                            
  Virus Strains                                                                                             
                                                                                                            
  JCPyV                                            [@R33]                                                   N/A
  SV40                                             [@R25]                                                   N/A
                                                                                                            
  Chemicals, Peptides, and Recombinant Proteins                                                             
                                                                                                            
  Ritanserin                                       Tocris Bioscience                                        Cat\#1955
  Hygromycin B                                     ThermoFisher Scientific                                  Cat\#10687010
  Geneticin (G418)                                 ThermoFisher Scientific                                  Cat\#10131035
  Puromycin                                        ThermoFisher Scientific                                  Cat\#A1113803
  Neuraminidase type II                            Sigma                                                    Cat\#N6514
                                                                                                            
  Critical Commercial Assays                                                                                
                                                                                                            
  QuikChange II Site directed mutagenesis kit      Agilent                                                  Cat\#200555
  QuikChange II XL Site Directed Mutagenesis Kit   Agilent                                                  Cat\#200521
  Q5 Site-Directed Mutagenesis Kit                 NEB                                                      Cat\#E0554S
  BioLuxCypridina Luciferase Assay kit             NEB                                                      Cat\#E3309L
  Fugene HD                                        Promega                                                  Cat\#E2311
  LipofectamineRNAiMAX                             ThermoFisher Scientific                                  Cat\#13778075
  Alexa Fluor 488 NHS Ester (Succinimidyl Ester)   ThermoFisher Scientific                                  Cat\#A200000
  Lipofectamine 3000                               ThermoFisher Scientific                                  Cat\#L3000008
                                                                                                            
  Experimental Models: Cell Lines                                                                           
                                                                                                            
  SVG-A cells (human fetal glial cells)            [@R18]                                                   N/A
  HEK293A cells                                    ATCC                                                     Cat\#CRL-1573; RRID:CVCL_0045
  HEK293T cells                                    ATCC                                                     Cat\#CRL-11268; RRID:CVCL_1926
  Lenti-X HEK293T cells                            Takara                                                   cat\#632180
  CV-1 (African green monkey)                      ATCC                                                     Cat\#CCL-70; RRID:CVCL_0229
                                                                                                            
  Oligonucleotides                                                                                          
                                                                                                            
  SignalSilence β-arrestin1 siRNA                  Cell Signaling Technologies                              Cat\#6218
  SignalSilence Control siRNA                      Cell Signaling Technologies                              Cat\#6568
  Mutagenesis primers see tables                   This paper                                               N/A
                                                                                                            
  Recombinant DNA                                                                                           
                                                                                                            
  lentiCRISPRv2 plasmid-puromycin                  Addgene                                                  Cat\#52961; RRID: Addgene_52961
  lentiCRISPRv2 plasmid-neomycin                   This paper                                               N/A
  lentiCRISPRv2 plasmid-hygromycin                 This paper                                               N/A
  pCMV-dR8.2                                       Addgene                                                  Cat\#8455; RRID: Addgene_8455
  pCMV-VSV-G                                       Addgene                                                  Cat\#8454; RRID: Addgene_8454
  5-HT~2A~R-pcDNA 3.1                              UMR cDNA resource center, University of Missouri-Rolla   Cat\#HTR02A0001
  5-HT~2B~R-pcDNA 3.1                              UMR cDNA resource center, University of Missouri-Rolla   Cat\#HTR02B0000
  5-HT~2C~R-pcDNA 3.1                              UMR cDNA resource center, University of Missouri-Rolla   Cat\#HTR02C0000
  5-HT~2A~R-YFP                                    [@R2]; [@R16]                                            N/A
  5-HT~2B~R-YFP                                    [@R2]; [@R16]                                            N/A
  5-HT~2C~R-YFP                                    [@R2]; [@R16]                                            N/A
  5-HT~2A~R-YFP-P180A                              This paper                                               N/A
  5-HT~2B~R-YFP-P160A                              This paper                                               N/A
  5-HT~2C~R-YFP-P159A                              This paper                                               N/A
  5-HT~2A~R-pcDNA 3.1-trunc before DRY-His         This paper                                               N/A
  5-HT~2A~R-pcDNA 3.1-trunc after DRY-His          This paper                                               N/A
  5-HT~2B~R-pcDNA 3.1-trunc before DRY-His         This paper                                               N/A
  5-HT~2B~R-pcDNA 3.1-trunc after DRY-His          This paper                                               N/A
  5-HT~2C~R-pcDNA 3.1-trunc before DRY-His         This paper                                               N/A
  5-HT~2C~R-pcDNA 3.1-trunc after DRY-His          This paper                                               N/A
  5-HT~2A~R-His-pcDNA 3.1                          This paper                                               N/A
  5-HT~2B~R-His-pcDNA 3.1                          This paper                                               N/A
  5-HT~2C~R-His-pcDNA 3.1                          This paper                                               N/A
  VP1-pwP vector                                   [@R9]                                                    N/A
  VP2-ph2p vector                                  [@R9]                                                    N/A
  VP3-ph2p vector                                  [@R9]                                                    N/A
  phSv40-Cluc                                      [@R9]                                                    N/A
                                                                                                            
  Software and Algorithms                                                                                   
                                                                                                            
  Blobfinder                                       Center for Image Analysis (Uppsala University)           <http://www.cb.uu.se/amin/BlobFinder/>
  Fiji                                             [@R31]                                                   <https://fiji.sc/>
  CRISPR design                                    Zhang Lab                                                <http://zlab.bio/guide-design-resources>
  QuikChange primer design tool                    Agilent                                                  <https://www.chem.agilent.com/store/primerDesignProgram.jsp>
  NEBaseChanger tool                               NEB                                                      <http://nebasechanger.neb.com/>

###### Highlights

-   JC virus interacts transiently with each of the 5-HT~2~ receptors(5-HT~2~Rs)

-   CRISPR-Cas9 genetic knockout of 5-HT~2~ receptors reduces infection

-   The second intracellular loop of each 5-HT~2~ receptor is sufficient for infection

-   A proline in each 5-HT~2~ receptor is critical to support infection
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